Tazemetostat - Epizyme
Alternative Names: Davico; E-7438; EPZ-6438; EZ-438; IPN-60200; Tavico; Tazemetostat hydrobromide - Epizyme; Tazestat - Epizyme; Tazverik; Zestastat - EpizymeLatest Information Update: 09 Jul 2024
At a glance
- Originator Epizyme
- Developer Eisai Co Ltd; Epizyme; Genentech; HUTCHMED; Ipsen; National Cancer Institute (USA); Pfizer
- Class Amides; Amines; Antineoplastics; Biphenyl compounds; Dihydropyridines; Morpholines; Small molecules
- Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors; SMARCA2 protein inhibitors; SMARCA4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Follicular lymphoma; Sarcoma
- Registered Non-Hodgkin's lymphoma
- Phase II CNS cancer; Diffuse large B cell lymphoma; Histiocytosis; Lymphoma; Mesothelioma; Neurofibrosarcoma; Ovarian cancer; Peritoneal cancer; Prostate cancer; Rhabdoid tumour; Solid tumours; Synovial sarcoma; Uterine cancer
- Phase I/II Bladder cancer; Non-small cell lung cancer
- No development reported B-cell lymphoma; Mantle-cell lymphoma
Most Recent Events
- 04 Jul 2024 Preregistration for Follicular lymphoma (Second-line therapy or greater) in China (PO)
- 04 Jul 2024 National Medical Products Administration (NMPA) of China accepts NDA for tazemetostat for Follicular lymphoma (Second-line therapy or greater) for review
- 31 May 2024 Efficacy and adverse events data from a phase-I/II clinical trials in Bladder cancer presented at 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)